Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.01, FiscalAI reports. The company had revenue of $0.61 million for the quarter, compared to the consensus estimate of $6.35 million. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 57.92%.
Voyager Therapeutics Price Performance
Shares of NASDAQ VYGR traded down $0.15 during trading hours on Thursday, reaching $1.72. The stock had a trading volume of 1,302,634 shares, compared to its average volume of 666,221. The business’s fifty day moving average is $2.61 and its two-hundred day moving average is $3.43. The company has a market cap of $105.98 million, a price-to-earnings ratio of -0.96 and a beta of 1.20. Voyager Therapeutics has a twelve month low of $1.68 and a twelve month high of $5.48.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on VYGR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Friday, October 9th. HC Wainwright reissued a “buy” rating on shares of Voyager Therapeutics in a research report on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.50.
Read Our Latest Report on VYGR
About Voyager Therapeutics
Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system.
Voyager’s research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system.
Further Reading
- Five stocks we like better than Voyager Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
